Phase I Trial of Intraperitoneal 212-Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy.

Trial Profile

Phase I Trial of Intraperitoneal 212-Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs 212 Pb TCMC trastuzumab (Primary)
  • Indications Breast cancer; Colon cancer; Endometrial cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors AREVA Med; Orano Med
  • Most Recent Events

    • 23 Jan 2018 According to an Orano Med media release, AREVA Med changed its name to Orano Med.
    • 29 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov records.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top